Merrimack Pharmaceuticals, Inc.
MACK · NASDAQ
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
|---|---|---|---|---|
| Market Cap | $213 | $192 | $177 | $176 |
| - Cash | $234 | $6 | $6 | $10 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | -$21 | $186 | $170 | $166 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$1 | $0 | -$1 | -$1 |
| % Margin | – | – | – | – |
| Net Income | -$24 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | – |
| EPS Diluted | -1.64 | -0.017 | -0.02 | -0.027 |
| % Growth | -9,720.4% | 14.4% | 28.8% | – |
| Operating Cash Flow | -$1 | -$0 | -$0 | -$1 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$1 | -$0 | -$0 | -$1 |